MCK - NYSE

McKesson Corporation

MCK·NYSE

$739.53

+0.37%

HealthcareMedical - Distribution

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$88.89B

EPS38.5500

P/E Ratio19.18

Earnings Date08/05/2026

75.14B

Assets

11%

3Y+19.0%

5Y+23.0%

10Y+33.0%

76.83B

Total Liabilities

11%

3Y+18.0%

5Y+41.0%

10Y+66.0%

-1.69B

Total Equity

3Y-5.0%

5Y-125.0%

10Y-116.0%

McKesson Corporation Funding & Solvency Profile

MCK · NYSE

Current Assets

Cash & Cash Equivalents5.69B

Net Receivables25.64B

Inventory23.00B

Other Current Assets1.06B

Total Current Assets55 B

Non-Current Assets

Property, Plant & Equipment4.28B

Goodwill & Intangible Assets11.49B

Long-Term Investments0.00

Other Non-Current Assets3.97B

Total Non-Current Assets8 B

Total Assets

75.14B

Financial Health Analysis

Current Ratio

0.90x

Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.

Working Capital

-6206000000

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

74% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

McKesson Corporation Balance Sheet

MCK • NYSE

McKesson Corporation Balance Sheet	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010	Mar 2009	Mar 2008	Mar 2007	Mar 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	5.7B	4.6B	4.7B	3.5B	6.3B	4B	3B	2.7B	2.8B	4B	5.3B	4.2B	2.5B	3.1B	3.6B	3.7B	2.1B	1.4B	2B	2.1B
Cash & Short-Term Investments	5.7B	4.6B	4.7B	3.5B	6.3B	4B	3B	2.7B	2.8B	4B	5.3B	4.2B	2.5B	3.1B	3.6B	3.7B	2.1B	1.4B	2B	2.1B
Net Receivables	25.6B	21.6B	19.4B	18.6B	19.2B	20B	18.2B	17.7B	18.2B	18B	15.9B	14.2B	10B	10B	9.2B	8.1B	7.8B	7.2B	6.6B	6.2B
Accounts Receivables	21.8B	18.5B	17B	16.3B	16.9B	16.9B	14.7B	14.1B	14.3B	14.3B	12.9B	12.4B	8.6B	8.4B	7.8B	7.1B	6.7B	6.2B	5.6B	6.2B
Other Receivables	3.9B	3.1B	2.4B	2.3B	2.3B	3B	3.6B	3.6B	3.9B	3.7B	3B	1.8B	1.4B	1.5B	1.3B	968M	1B	984M	953M	0.0
Inventory	23B	21.1B	19.7B	18.7B	19.2B	16.7B	16.7B	16.3B	15.3B	15.3B	14.3B	13.3B	10.3B	10.1B	9.2B	9.4B	8.5B	9B	8.2B	7.3B
Prepaids	0.0	0.0	0.0	898M	665M	617M	529M	443M	672M	1.1B	1.1B	1.9B	404M	404M	333M	257M	261M	211M	221M	522M
Other Current Assets	1.1B	626M	513M	4.5B	12M	906M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	962M	962M
Total Current Assets	55.4B	48B	44.3B	46.2B	45.4B	42.2B	38.5B	37.1B	36.9B	38.4B	36.7B	32.6B	23.2B	23.6B	22.4B	21.5B	18.7B	17.8B	17.9B	16.9B
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	4.3B	4B	3.8B	3.6B	4.7B	4.3B	2.5B	2.5B	2.3B	2.3B	2B	2.2B	1.3B	1B	991M	851M	796M	775M	684M	671M
Goodwill	10B	10.1B	9.9B	9.5B	9.5B	9.4B	9.4B	10.9B	10.6B	9.8B	9.8B	9.9B	6.4B	5B	4.4B	3.6B	3.5B	3.3B	3B	1.7B
Intangible Assets	1.5B	2.1B	2.3B	2.1B	2.9B	3.2B	3.7B	4.1B	3.7B	3B	3.4B	5B	2.3B	1.8B	1.6B	785M	882M	860M	779M	128M
Goodwill & Intangible Assets	11.5B	12.2B	12.2B	11.5B	12.4B	12.5B	13B	15B	14.3B	12.8B	13.3B	14.9B	8.7B	6.8B	6B	4.4B	4.4B	4.2B	3.8B	1.8B
Long-Term Investments	0.0	348M	312M	0.0	72M	170M	3.5B	3.7B	4.1B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	179M
Tax Assets	0.0	0.0	-312M	0.0	-72M	-170M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-179M
Other Non-Current Assets	4B	2.8B	2B	1.9B	2.6B	2.3B	2.1B	2B	3.4B	3B	1.9B	2B	1.6B	1.7B	1.6B	1.5B	1.4B	1.8B	1.6B	1.5B
Total Non-Current Assets	19.7B	19.5B	18B	17.1B	19.6B	19B	21.2B	23.2B	24B	18.1B	17.2B	19.2B	11.6B	9.5B	8.5B	6.7B	6.6B	6.8B	6.1B	4.1B
Total Assets	75.1B	67.4B	62.3B	63.3B	65B	61.2B	59.7B	60.4B	61B	56.6B	53.9B	51.8B	34.8B	33.1B	30.9B	28.2B	25.3B	24.6B	23.9B	21B
LIABILITIES
CURRENT LIABILITIES
Total Payables	55.3B	47.1B	42.5B	38.1B	39B	37.2B	33.9B	32.2B	31B	28.6B	25.2B	21.1B	16.1B	16.1B	14.1B	13.3B	11.7B	12B	10.9B	10.1B
Accounts Payable	55.3B	47.1B	42.5B	38.1B	39B	37.2B	33.9B	32.2B	31B	28.6B	25.2B	21.1B	16.1B	16.1B	14.1B	13.3B	11.7B	12B	10.9B	10.1B
Accrued Expenses	4.8B	4.9B	4.2B	4.5B	4B	3.3B	3.4B	3.4B	3B	3.9B	3.8B	4B	1.9B	2.1B	1.9B	1.6B	2.5B	2.1B	2.1B	0.0
Short Term Debt	1.2B	50M	968M	799M	742M	1.1B	330M	1.1B	1.2B	1.6B	1.7B	1.7B	352M	908M	417M	3M	219M	2M	155M	26M
Capital Lease Obligations (Current)	258M	295M	299M	297M	390M	354M	0.0	-3.2B	-2.9B	-3.8B	0.0	-205M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	63M	346M	919M	1.1B	1.2B	1.4B	1.4B	1.3B	1.2B	1.1B	1.2B	1B	827M
Other Current Liabilities	0.0	0.0	0.0	4.7B	9M	683M	0.0	-63M	0.0	0.0	1.8B	1.6B	1.6B	1.1B	1B	977M	0.0	0.0	962M	2.6B
Total Current Liabilities	61.6B	52.4B	48B	48.5B	44.1B	42.6B	37.6B	36.7B	35.6B	35.1B	33.5B	29.5B	21.4B	21.7B	18.7B	17B	15.6B	15.3B	15.1B	13.5B
NON-CURRENT LIABILITIES
Long Term Debt	4.5B	5.6B	4.6B	5.1B	6.4B	6.3B	7.3B	6.8B	7.3B	6.5B	8.2B	8.9B	4.5B	3.1B	3.6B	2.3B	2.3B	1.8B	1.8B	965M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8B	-1.6B	-1.6B	-1.1B	-1B	0.0	0.0	0.0	0.0	385M
Deferred Tax Liabilities (Non-Current)	1B	917M	1.4B	1.4B	1.4B	2.3B	3B	2.8B	3.7B	2.7B	1.8B	1.6B	1.6B	1.1B	1B	0.0	0.0	0.0	0.0	-385M
Other Non-Current Liabilities	8.3B	8.7B	8.4B	8.8B	9.8B	1.7B	2.1B	2.6B	1.8B	1.8B	1.9B	2.9B	1.8B	1.5B	1.4B	1.4B	1.2B	1.3B	741M	599M
Total Non-Current Liabilities	15.2B	16.7B	15.9B	16.6B	19.5B	11.9B	12.4B	12.2B	12.8B	11.1B	10.9B	11.9B	6.4B	4.6B	4.9B	3.6B	3.5B	3.1B	2.5B	1.6B
Capital Lease Obligations	1.7B	1.8B	1.7B	1.7B	2.3B	2B	43M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	76.8B	69B	63.8B	65.1B	63.6B	54.5B	50B	48.9B	48.4B	46.1B	44.4B	41.4B	27.7B	26.3B	23.7B	20.7B	19.1B	18.5B	17.7B	15.1B
SHAREHOLDERS' EQUITY
Treasury Stock	-27.4B	-24.1B	-21B	-17B	-13.7B	-12.9B	-8.9B	-7.7B	-6B	-3.7B	-10B	-9.5B	-9.4B	-8.2B	-6.5B	-4.5B	-4.1B	-3.9B	-2.2B	-1.2B
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13M	33M	100M
Common Stock	3M	3M	3M	2M	2M	2M	3M	3M	3M	3M	4M	4M	4M	4M	4M	4M	4M	4M	3M	3M
Additional Paid-In Capital	8.4B	8B	7.7B	7.3B	6.9B	6.7B	6.4B	6.2B	6B	5.8B	7B	6.6B	6.1B	5.6B	5.3B	4.7B	4.4B	4.3B	3.7B	3.2B
Retained Earnings	17.9B	15B	12.3B	9B	8.2B	13B	12.4B	13B	13.2B	8.4B	12.7B	11.5B	10.4B	9.5B	8.3B	7.2B	6.1B	5.6B	4.7B	3.9B
Accumulated Other Comprehensive Income/Loss	-932M	-881M	-905M	-1.5B	-1.5B	-1.7B	-1.8B	-1.7B	-2.1B	-1.6B	-1.7B	-3M	-65M	5M	87M	6M	-179M	139M	-2M	-45M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	-2M	-1M	-2M	-2M	-7M	23M	14M	4M	0.0	0.0	-8M	0.0	0.0	0.0
Total Stockholders' Equity	-2.1B	-2B	-1.9B	-2.3B	-21M	5.1B	8.1B	9.8B	11.1B	8.9B	8B	8.5B	7.1B	6.8B	7.2B	7.5B	6.2B	6.1B	6.3B	5.9B
Total Equity	-1.7B	-1.6B	-1.5B	-1.8B	1.4B	6.7B	9.7B	11.5B	12.6B	10.4B	9.5B	10.3B	7.1B	6.8B	7.2B	7.5B	6.2B	6.1B	6.3B	5.9B
Minority Interest	380M	372M	367M	480M	1.5B	1.6B	1.6B	1.7B	1.5B	1.5B	1.5B	1.8B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	75.1B	67.4B	62.3B	63.3B	65B	61.2B	59.7B	60.4B	61B	56.6B	53.9B	51.8B	34.8B	33.1B	30.9B	28.2B	25.3B	24.6B	23.9B	21B
Total Investments	0.0	348M	312M	0.0	72M	170M	3.5B	3.7B	4.1B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	179M
Total Debt	7.4B	7.4B	7.3B	7.5B	9.4B	9.4B	7.6B	7.9B	8.5B	8.2B	9.8B	10.7B	4.9B	4B	4B	2.3B	2.5B	1.8B	2B	991M
Net Debt	1.7B	2.8B	2.6B	4B	3.1B	5.4B	4.6B	5.2B	5.8B	4.1B	4.5B	6.5B	2.4B	831M	392M	-1.4B	400M	435M	4M	-1.2B
Shares Outstanding	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995	124,999,995

SEC Filings

MCK - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-K 10-K 2026 FY FY	May 08, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 06, 2026	April 01, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	March 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 03, 2026	2026	View Filing
10-Q 10-Q 2025 Q4 Q4	February 04, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 04, 2026	February 04, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing

Showing 1 to 10 of 522 filings

Related Guides

Blog Categories

Continue your MCK research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.